Oncotherapy Science
Basic Information
- Stock Code
- 4564
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Kanagawa Prefecture
- Establishment Year
- April 2001
- Listing Year
- December 2003
- Official Website
- https://www.oncotherapy.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexel Pharma, PeptiDream, Ribomic, SanBio, Helios, BrightPath, Solasia, RenaScience, QualiPs, Takara Bio, Japan Tissue Engineering
Overview
Oncotherapy Science is a Japanese drug discovery venture founded in 2001, specializing in the development of gene-related pharmaceuticals such as cancer treatment vaccines, with strengths in joint research with universities and partnerships with pharmaceutical companies.
Current Situation
As of 2023, Oncotherapy Science has consolidated sales of approximately 5.2 billion yen and is a university-spun venture in the biotech pharmaceuticals sector focusing on cancer drug development. It advances innovative cancer vaccine research and development through collaborations with the University of Tokyo and the University of Chicago. The company does not conduct in-house manufacturing but adopts a business model of licensing manufacturing and sales rights to major pharmaceutical companies, securing stable contract income. Research facilities are located in Kanagawa Science Park and King's Skyfront in Kawasaki City, Kanagawa Prefecture, with cutting-edge pharmaceutical development environments. Moving forward, it aims for growth through expansion of partnerships and technological innovations in new drug development, planning commercialization of multiple therapies in the late 2020s. In terms of sustainability, it focuses on pharmaceutical safety and ethical compliance, while also promoting community collaborations and social contribution activities. In the competitive bio drug discovery field, it is working to establish a competitive advantage based on its high technological capabilities.
Trivia
Interesting Facts
- Drug discovery venture spun out from the University of Tokyo's Institute of Medical Science
- Founder is a professor at the same institute with significant influence domestically and internationally
- Business model of not manufacturing pharmaceuticals in-house but consigning to pharma companies
- One of the few companies continuing international joint research with the University of Chicago
- Top-tier patent holdings in cancer vaccine field within the industry
- Base located in Kanagawa Prefecture's science and technology special zone
- Speed in immediately converting research outcomes to licensing contracts
- Research facilities consolidated in King's Skyfront
- Possesses domestically top-class gene analysis technology
- Yusuke Nakamura holds over 8% of shares as a specific shareholder
- Pioneer among university-spun ventures listed on Tokyo Stock Exchange Growth Market
- Business foundation supported by transaction relationships with several major pharmaceutical companies
- Stable management base over 20 years since founding
- Head office relocation to Higashida-machi, Kawasaki-ku due to facility modernization
- Diversified expansion into reagents and analysis services beyond pharmaceuticals
Hidden Connections
- International joint research with University of Chicago accelerates US clinical trials
- Risk diversification achieved by consigning manufacturing and sales to major pharmaceutical companies
- Utilizes research network of University of Tokyo's Institute of Medical Science
- Contributes to formation of Kawasaki City's medical and science technology cluster
- Management of drug discovery-related patents is key to business revenue
- Cancer vaccine manufacturing rights contracts are a rare structure in the industry
- While specialized in R&D, also deploying diverse bio products
- Oncovex in view for therapeutic drug deployment domestically and internationally
Future Outlook
Growth Drivers
- Global increase in demand for cancer immunotherapy
- Technological innovations in gene pharmaceuticals
- Expansion of joint research with pharmaceutical companies
- Improved drug discovery efficiency through AI utilization
- Advancement of international clinical trials
- Enhanced research capabilities through securing advanced talent
- Progress in developing new target molecules
- Regulatory easing and shortened pharmaceutical approval periods
- Stabilization of licensing revenues
- Expanding societal expectations for sustainable medical technologies
- Support from Kanagawa Prefecture's science and technology policies
- Strengthening of global partnerships
Strategic Goals
- Launch several types of cancer treatment drugs to market
- Expand overseas market sales ratio to over 50%
- Halve drug discovery time using AI technology
- Double the number of partnerships with major pharmaceutical companies
- Obtain international certifications for sustainability and ethical research
- Global deployment of clinical trial bases
- Improve employee diversity by over 50%
- Maintain R&D expenses at 40% of sales
- Expand and strengthen intellectual property portfolio
- Enhance corporate value through coexistence with local communities
Business Segments
Drug Discovery Research Support
- Overview
- Provides gene-related technologies and research support services necessary for pharmaceutical development to promote drug discovery for contract partners.
- Competitiveness
- Advanced gene analysis technology and research capabilities through university collaborations
- Customers
-
- Major pharmaceutical companies
- Biotech ventures
- University research institutions
- Public research institutes
- Contract research organizations
- Medical device manufacturers
- Pharmaceutical development companies
- Diagnostic drug manufacturers
- Formulation manufacturers
- CRO (Contract Research Organizations)
- Products
-
- Gene analysis services
- Gene probe development
- Bio reagents
- Pathology analysis support
- Data analysis via software
- Drug discovery platform provision
- Provision of molecular targeted drug candidates
- Vaccine design support
Pharmaceutical Development Licensing
- Overview
- Licenses in-development pharmaceuticals to pharmaceutical companies to support market deployment of therapeutic drugs.
- Competitiveness
- Product development capabilities utilizing unique university-originated technologies
- Customers
-
- Domestic pharmaceutical companies
- Overseas pharmaceutical companies
- Generic drug manufacturers
- Medical institutions
- CRO companies
- Products
-
- Therapeutic vaccine development results
- Exclusive manufacturing and sales rights
- Technology transfer contracts
- Joint research contracts
Research and Development Equipment and Materials Provision
- Overview
- Segment providing equipment and materials for drug discovery and diagnostic research to research institutions.
- Competitiveness
- Customization capabilities for specialized reagents
- Customers
-
- Universities
- Research institutes
- Pharmaceutical company R&D departments
- Bio labs
- Products
-
- Gene analysis reagents
- Cell culture-related materials
- Diagnostic test kits
- Biosensors
Joint Research Operations
- Overview
- Promotes joint research with academic institutions and industry, focusing on foundational research for new pharmaceuticals.
- Competitiveness
- Research system led by university professors and diverse partnerships
- Customers
-
- Universities
- Public research institutions
- Pharmaceutical companies
- Medical institutions
- Products
-
- Joint vaccine development
- Gene technology research
- Verification of new therapies
- Joint management of intellectual property
Data Analysis and IT Services
- Overview
- Provision of drug discovery support data analysis services utilizing the latest IT technologies.
- Competitiveness
- Expertise in AI and data analysis technologies
- Customers
-
- Pharmaceutical companies
- Research institutions
- Biotech ventures
- CROs
- Products
-
- Drug discovery data integration platform
- AI analysis services
- Bioinformatics
- Research tool provision
Intellectual Property Management
- Overview
- Supports technology commercialization and business through intellectual property management and distribution.
- Competitiveness
- Extensive patent portfolio and negotiation capabilities
- Customers
-
- Pharmaceutical companies
- Research institutions
- Investors
- Partner companies
- Products
-
- Patent management
- Technology transfer licensing
- Technology evaluation
- Contract negotiation support
Overseas Partnership Operations
- Overview
- Advances global expansion strategies through collaborations with overseas institutions.
- Competitiveness
- Track record of collaborations with prestigious overseas institutions like the University of Chicago
- Customers
-
- Overseas pharmaceutical companies
- Foreign investment firms
- International academic institutions
- Products
-
- International joint research
- Overseas sales licensing
- Technology export
- Market research
Clinical Trial Support Services
- Overview
- Provides clinical trial support services in new drug development stages, contributing to swift approvals.
- Competitiveness
- Evaluation system utilizing advanced gene analysis technology
- Customers
-
- Pharmaceutical companies
- CROs
- Medical institutions
- Products
-
- Clinical trial data analysis
- Patient recruitment support
- Clinical trial protocol development
Medical Education Support
- Overview
- Implements education support and awareness activities for medical professionals.
- Competitiveness
- High-quality education programs in collaboration with experts
- Customers
-
- Medical institutions
- Universities
- Medical professional associations
- Products
-
- Seminar hosting
- Provision of teaching materials
- Training for specialists
Diagnostic Technology Development
- Overview
- Supports development and commercialization of new diagnostic technologies.
- Competitiveness
- Advancement of diagnostic technologies linked with drug discovery
- Customers
-
- Testing equipment manufacturers
- Medical institutions
- Research institutes
- Products
-
- Gene testing technology
- Immunodiagnostic kits
- Biosensor development
Technology Consulting
- Overview
- Provides consulting services on technical and business aspects.
- Competitiveness
- Practical proposals leveraging industry knowledge
- Customers
-
- Biotech companies
- Pharmaceutical companies
- Investment institutions
- Products
-
- Technology evaluation reports
- Business strategy formulation support
- Technology introduction support
Manufacturing Outsourcing Management
- Overview
- Deploys services managing product manufacturing in collaboration with outsourcing partners.
- Competitiveness
- Strong trusted relationships with outsourcing partners
- Customers
-
- Major pharmaceutical companies
- Biotech companies
- Products
-
- Manufacturing outsourcing contract management
- Quality control guidance
Competitive Advantage
Strengths
- Advanced gene analysis technological capabilities
- Long-term joint research framework with universities
- Specialized cancer treatment drug development capabilities
- Management focused on biopharmaceutical drug discovery
- Track record of partnerships with major pharmaceutical companies
- Clear separation of R&D and licensing
- Base in Kawasaki City's advanced research facilities
- Strong patent portfolio for technology transfer
- Founder's researcher network
- Proprietary vaccine platform
- Adoption of flexible business model
- Access to domestic and international markets
- Diversified R&D fields
- High personnel quality through specialized staff
- Rapid commercialization system for research outcomes
Competitive Advantages
- Possesses cutting-edge research technologies through university collaborations
- Reliably links contract revenues with pharmaceutical companies
- Unique technological accumulation in vaccine therapy field
- Established position in domestic biopharmaceutical drug discovery market
- Combines diverse products and services
- Strong management capabilities for patents and intellectual property
- Supportive environment from Kawasaki's science and technology hub
- Deepens expertise by specializing in cancer treatment field
- Grasps global trends through international joint research
- Diversified and stable funding
- Securing and development of high-caliber R&D personnel
- Risk diversification through licensing
- Rapid market entry and promotion of external collaborations
- Drug discovery data analysis capabilities using advanced IT
- Cost-efficient operations through manufacturing outsourcing
Threats
- Intense research competition in biopharmaceutical drug discovery
- Risk of development failure for new technologies
- Impact from policy changes by major pharmaceutical companies
- Complexity and delays in pharmaceutical approvals
- Impact from fluctuations in funding environment
- Burden of adapting to international regulations and legal amendments
- Rapid changes in market needs
- Patent dispute risks
- Large-scale investments and resource mobilization by competitors
- Uncertainty from external environments like emerging infectious diseases
- Challenges in commercializing research outcomes
- Decline in technological capabilities due to talent outflow
Innovations
2023: Strengthened Joint Research with University of Chicago
- Overview
- After recruiting Professor Yusuke Nakamura, advanced cancer vaccine research and progressed to clinical trial stages in the US.
- Impact
- Promotes product commercialization through expansion of global clinical trials
2022: Development of Next-Generation Cancer Immunotherapy Technology
- Overview
- Built a vaccine platform combined with immune checkpoint inhibitors.
- Impact
- Establishes foundation for improved treatment efficacy and new market creation
2024: Introduction of AI Drug Discovery Data Analysis System
- Overview
- Developed a new system to accelerate gene analysis and drug candidate exploration using AI technology.
- Impact
- Achieved reduction in R&D period and costs
2021: Concluded Joint Manufacturing Contract with Major Pharma
- Overview
- Achieved resource efficiency and sales channel expansion through contract specialized in manufacturing and sales with a major company.
- Impact
- Secures stable revenue and enhances market competitiveness
2020: Development of Gene-Related Marker Testing Technology
- Overview
- Advanced productization of gene marker test kits supporting early cancer detection.
- Impact
- Monetizes diagnostic technology field
Sustainability
- Thorough safety and quality management in pharmaceutical manufacturing
- Conduct of ethical medical research
- Promotion of local medical support activities
- Improvement of energy efficiency
- Promotion of diversity and inclusion
- Ensuring transparency of research outcomes
- Operation of research bases aiming to reduce environmental impact
- Ensuring employee health and safety
- Proper management of intellectual property rights
- Support for local science education
- CO2 reduction through remote work introduction
- Strengthening environmental considerations in supply chain